Mycobacterium bovis is a bacterium belonging to the Mycobacterium tuberculosis complex, known for causing bovine tuberculosis in cattle. This pathogen can also infect a wide range of mammals, including humans, leading to zoonotic transmission. Bovine tuberculosis poses a significant threat to livestock industries and has public health implications due to the potential transmission to humans through consumption of contaminated dairy products or direct contact with infected animals. In humans, M. bovis infection can result in pulmonary and extrapulmonary tuberculosis. Control measures for M. bovis include testing and culling infected animals, pasteurization of milk to reduce transmission through dairy products, and vaccination programs in some regions. The Bacillus Calmette-Guérin (BCG) vaccine, initially developed to protect against Mycobacterium tuberculosis, also provides partial protection against M. bovis. M. bovis has a complex genome, and understanding its virulence factors and mechanisms of transmission is essential for developing effective control strategies. Ongoing research focuses on improving diagnostic tools, vaccines, and management practices to mitigate the impact of M. bovis on both animal and human health.
Khursheed Anwer
IMUNON, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Khursheed Anwer
IMUNON, United States
Ping Xie
Rutgers University, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Lara Isis Teodoro
Mayo Clinic, United States
Ahmed Abdulazeez
BHRUT Trust, United KingdomSubmit your abstract Today
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France